SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as the community celebrates the recovery of its ticker symbol and continues to push for broader visibility while emphasizing their commitment to an organic, long-term project. Investors are actively discussing the potential for a forthcoming chart listing and rallying around a narrative of collective building to differentiate themselves from short-term memecoin scams.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors focus on its critical role as the gatekeeper of AI infrastructure, buoyed by massive order backlogs and a recent breakthrough in lithography technology that promises a 50% boost in chip output by 2030. While some market participants debate potential valuation stretching, the community remains intensely focused on the company's monopoly on EUV systems as a non-negotiable bottleneck for global semiconductor scaling.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing heightened community discussion as investors weigh its aggressive infrastructure expansion against ongoing concerns regarding potential equity dilution from its sizable at-the-market offering. The stock is currently being closely monitored for a potential breakout as traders look for news on site energizations and new hyperscaler partnerships to confirm its competitive standing within the evolving AI and data center sector.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. is trending as investors focus on its pivot to building a domestic heavy rare earth metallization facility designed to replace Chinese-sourced materials in U.S. defense supply chains. The community is actively debating the company's long-term potential as a critical defense contractor against concerns regarding its pre-revenue status and capital structure.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense market volatility and increased short interest following a board-level shakeup, with the community actively debating whether the resignation of a key board member signals deeper governance issues or a buying opportunity. Traders are heavily focused on the company's strong fundamentals and upcoming earnings as potential catalysts to trigger a short squeeze against a backdrop of ongoing institutional accumulation.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Investors are actively flocking to UVIX as a hedge against rising geopolitical tensions in the Middle East and concerns over oil supply disruptions following the closure of the Strait of Hormuz. The community is heavily debating whether the current market stability is a temporary lull driven by political rhetoric or a fragile calm before a significant volatility breakout, fueling intense discussion around potential black swan events.

TOSHI

TOSHI is trending as the community debates its long-term potential as the face of the Base ecosystem, with investors actively discussing accumulation strategies during current market volatility. Sentiment is polarized, as some members express frustration over price performance while others highlight technical indicators like bullish divergences as signs of a potential reversal.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Delcath Systems is trending due to the anticipation of late-breaking CHOPIN trial data being presented at ESMO, alongside investor scrutiny regarding revised revenue guidance and the impact of the 340b pricing program. The community remains highly focused on the stock's long-term valuation relative to its Phase 2 pipeline progress, despite recent short-term volatility and downward pressure on price targets.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is facing significant selling pressure amid broader market volatility, compounded by recent class-action litigation and a cautious price target adjustment from analysts. While the community is actively debating the stock's long-term value and recent acquisition strategy, sentiment is polarized between long-term investors viewing current levels as a deep discount and traders wary of the ongoing technical breakdown.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

The AIRCOIN community is rallying behind a 'hold culture' narrative, fueled by significant supply locks through its 'Airlock' mechanism and daily engagement efforts. Investors are actively contrasting the project's long-term building focus and community-owned treasury against the typical volatility and 'rug-pull' risks of other memecoins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alto Neuroscience (NYSE:ANRO) Trading Down 6.3%  - Time to Sell?

Alto Neuroscience (NYSE:ANRO) Shares Down 6.3% - What's Next...

Q1 Earnings Estimate for ANRO Issued By HC Wainwright

Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Alto Neuroscience in a research note issued on Thursday...

Alto Neuroscience (NYSE:ANRO) Given New $38.00 Price Target at Robert W. Baird

Robert W. Baird decreased their price target on shares of Alto Neuroscience from $41.00 to $38.00 and set an "outperform" rating on the stock in a research note on Thursday...

<ul class="summary-bullets"><li>H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience.</li><li>Baird cut Alto’s price target to $38 from $41 but said the company’s depression pipeline remains the key driver of its valuation.</li><li>Jones Research’s latest price target implies a potential 100% upside to the stock’s current price.</li></ul>Shares of Alto Neuroscience (ANRO) slid about 7% on Thursday after disappointing results from a schizophrenia treatment study prompted multiple brokerages to become more cautious on the stock.On Wednesday, Alto Neuroscience <a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-schizophrenia-study-fails/cZ7HygQRIFi">said</a> its experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 Proof-of-Concept study. ALTO-101 did not show meaningful improvements in brain activity or cognitive measures compared to placebo.As a result, the biotech firm will not continue developing the drug for this use and will shift focus to other programs, including ALTO-207 for treatment-resistant depression. The company is also exploring partnership opportunities for a modified version of ALTO-101 that showed better safety and drug behavior.<h2 class="st-heading-2">Analyst Sees Pullback As Attractive Entry Point</h2>Jones Research cut Alto Neuroscience’s price target to $44 from $49, but kept a ‘Buy’ rating, according to The Fly. This implies a potential 100% upside to the stock’s current price of around $22.Analyst Justin Walsh said that while the stock’s weakness is justified, the market is underestimating Alto’s broader pipeline and sees the pullback as an attractive entry point.H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience, as the program was not a key part of its valuation, according to The Fly. The brokerage also highlighted the company’s strong cash position of $275 million, which supports its pipeline. H.C. Wainwright maintained its ‘Buy’ rating and $50 price target.Baird cut the company’s price target to $38 from $41 and maintained an ‘Outperform’ rating. Analyst Brian Skorney called the ALTO-101 Phase 2 failure disappointing, though expectations were already modest given the challenges in schizophrenia treatment. The firm said Alto’s depression pipeline remains the key driver of its valuation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/ANRO">ANRO</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user had expected a bigger drop.<stembedurl>http://stocktwits.com/Stef_DL/message/649289943</stembedurl>Year-to-date, the stock has gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/snbr-stock-on-track-to-decline-for-12th-straight-session/cZ7x67bRI8o">SNBR Stock On Track To Decline For 12th Straight Session – Retail Sees Buying Opportunity If Stock Dips Below $1</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point

Alto Neuroscience’s experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 study, leading to price target cuts from multiple brokerages.

Equity

HC Wainwright Reaffirms Buy Rating for Alto Neuroscience (NYSE:ANRO)

HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Alto Neuroscience in a research note on Thursday...

JonesTrading Issues Pessimistic Forecast for Alto Neuroscience (NYSE:ANRO) Stock Price

JonesTrading reduced their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a "buy" rating on the stock in a research report on Thursday...

Alto Neuroscience (NYSE:ANRO) Shares Gap Down After Analyst Downgrade

Alto Neuroscience (NYSE:ANRO) Shares Gap Down After Analyst Downgrade...

Wedbush Lowers Alto Neuroscience (NYSE:ANRO) Price Target to $21.00

Wedbush reduced their target price on Alto Neuroscience from $22.00 to $21.00 and set a "neutral" rating on the stock in a report on Thursday...

Alto Neuroscience (NYSE:ANRO) Earns Buy Rating from Chardan Capital

Chardan Capital reissued a "buy" rating and set a $30.00 target price on shares of Alto Neuroscience in a research report on Thursday...

Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Dow futures down 400 points, Alto Neuroscience shares dip 13.6% after Phase 2 trial results, other stocks also falling in pre-market trading.read more...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.54	--	--	N/A
Q4 '25	-$0.53	-$0.46	13.41%	BEAT
Q3 '25	-$0.67	-$0.52	22.10%	BEAT
Q2 '25	-$0.60	-$0.65	-8.58%	MISSED
Q1 '25	-$0.61	-$0.56	7.98%	BEAT

ANRO
Alto Neuroscience Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest ANRO News

ANROAlto Neuroscience Inc.